DsRNA-VGSCT6 application at the larval stage does not affect vitality and behavior of treated mosquitoes. (A-B) Percentage of immature mortality (larvae and/or pupae) after dsRNA treatment (dsRNA-Random or dsRNA-VGSCT6) in the Rockefeller strain (A) and Rio de Janeiro strain (B). Data are shown as the mean ± standard deviation of three treatment replicates from two independent experiments. (C-D) Sex ratio in the Rockefeller (C) and Rio de Janeiro (D) strains after dsRNA treatment with dsRNA-Random or dsRNA-VGSCT6. Data are shown as the mean ± standard deviation of three treatment replicates of two independent experiments. (E-F) Percentage of blood fed females in the Rockefeller (E) and Rio de Janeiro (F) strains after dsRNA treatment (dsRNA-Random or dsRNA-VGSCT6) in the larval stage. Data are shown as the mean ± standard deviation of three treatment replicates of two independent experiments. (G-H) Number of eggs per female in the Rockefeller (G) and Rio de Janeiro (H) strains after dsRNA treatment (dsRNA-Random or dsRNA-VGSCT6) in the larval stage. Data are shown as the mean ± standard deviation of three treatment replicates of two independent experiments. (I-J) Hatching rate in the Rockefeller (I) and Rio de Janeiro (J) strains after treatment with dsRNA-Random or dsRNA-VGSCT6 in the larval stage. Data are shown as the mean ± standard deviation of three treatment replicates of two independent experiments. (TIFF 297 kb)